Sci & Tech

underwater-drones-

US Navy seeks new underwater drones to help contain submarine threat

Share:

— The U.S. Navy seeks to upgrade its fleet of autonomous underwater sensor gliders, devices used to provide data to attack

Share:
pollution-climate-change

Bill Gates: Solving Covid easy compared with climate

Share:

Fifty-one billion and zero – the two numbers Bill Gates says you need to know about climate. Solving climate change

Share:
UAE-MARS-MISSION-

UAE becomes the first Arab country to reach Mars

Share:

KEY POINTS The Emirates Mars mission, named the Hope probe, reached Mars’ orbit at 7:42 p.m. Tuesday local time and

Share:
B1117-SARS-CoV-2-Coronavirus-Variant-2048×1536-1

The science you need to understand about COVID-19 variants and vaccines

Share:

The SARS-CoV-2 virus mutates fast. That’s a concern because these more transmissible variants of SARS-CoV-2 are now present in the U.S., U.K. and South

Share:
JNJ-vaccine-covid-19

Johnson & Johnson seeks FDA ok for its Single-Shot COVID-19 Vaccine

Share:

Johnson & Johnson intends to distribute vaccine to the U.S. government immediately following authorization, and expects to supply 100 million

Share:
HANDS-AND-FACE-TRANSPLANT

‘New chance at life’: Man gets face, hands in rare surgery 

Share:

By MARION RENAULT and MARSHALL RITZEL NEW YORK (AP) — Almost six months after a rare face and hands transplant,

Share:
Human-Lung-Cells-Infected-With-SARS-CoV-2

How COVID-19 damages lung cells within hours – and what drugs could halt the infection

Share:

Multipronged BU research team finds 18 FDA-approved drugs that could halt coronavirus infection earlier. What if scientists knew exactly what

Share:
coronavirus vaccination

Recovered from COVID-19? Why you still need a vaccine

Share:

Clinical Contributors to this Story Thomas Bader, M.D. contributes to topics such as Medical Quality. Are you one of the millions of

Share:
JnJ-vaccine

Johnson & Johnson’s single shot COVID19 vaccine less effective

Share:

Johnson & Johnson’s single-shot Covid-19 vaccine has an overall efficacy of 66 percent, the company announced Friday, following results from

Share: